BREAKING: Futures Rise On Trump Comments, EarningsUnited Therapeutics (UTHR) on Wednesday reported adjusted earnings of $7.16 per share on $799.5 million in third-quarter sales.In response, United Therapeutics stock slipped a fraction to 412.50. Still, shares have a strong IBD Digital Composite Rating of 96, putting them in the top 4% of all stocks in terms of fundamental and technical measures.Analysts polled by FactSet expected United Therapeutics to earn $7.32 per share and report $813 million in sales. ...

United Therapeutics (UTHR) came out with quarterly earnings of $7.16 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.92%. A quarter ago, it was expected that this drugmaker would post earnings of $6.8 per share when it actually produced earnings of $6.41, delivering a surprise of -5.74%.Over the last four quarters, the com ...

Financial Performance - Total revenues for the third quarter of 2025 increased by 7% year-over-year to $799.5 million, compared to $748.9 million in the third quarter of 2024[2] - Net income for the third quarter of 2025 rose by 10% to $338.7 million, up from $309.1 million in the same period last year[2] - Total revenues for Q3 2025 reached $799.5 million, an increase of 6.6% compared to $748.9 million in Q3 2024[29] - Operating income for Q3 2025 was $388.5 million, up from $343.1 million in the same quarter last year, reflecting a growth of 13.2%[29] - Net income for Q3 2025 was $338.7 million, compared to $309.1 million in Q3 2024, representing an increase of 9.6%[29] - Basic net income per share increased to $7.73 in Q3 2025 from $6.93 in Q3 2024, a rise of 11.5%[29] Revenue Sources - Tyvaso total revenues grew by 10% to $478.0 million, driven by a 22% increase in Tyvaso DPI sales to $336.2 million[3][5] - Orenitram revenues increased by 16% to $131.1 million, primarily due to an increase in quantities sold[3][7] Expenses - Research and development expenses rose by 23% to $127.5 million, attributed to increased expenditures on manufactured organ projects and a $5.0 million milestone payment for drug delivery technologies[12][13] - Selling, general, and administrative expenses decreased by 17% to $182.6 million, primarily due to a significant reduction in litigation accrual[15] Tax and Equity - The effective income tax rate for the third quarter of 2025 was 23%, up from 20% in the same quarter of 2024[19] - The company entered into accelerated share repurchase agreements to repurchase approximately $1.0 billion of common stock in August 2025 and March 2024, totaling $2.0 billion[20] Market and Growth Potential - The number of patients using Tyvaso continued to grow, contributing to increased commercial utilization following the Medicare Part D benefit redesign under the Inflation Reduction Act[6] - The company anticipates that the breakthrough results from the TETON-2 study in idiopathic pulmonary fibrosis could significantly broaden its therapeutic reach and accelerate growth[1] - Forward-looking statements indicate confidence in sustaining revenue growth and broadening therapeutic reach through ongoing studies[24] Assets and Corporate Structure - Cash, cash equivalents, and marketable investments totaled $4,334.9 million as of September 30, 2025[31] - Total assets amounted to $7,351.1 million, while total liabilities were $760.9 million, resulting in total stockholders' equity of $6,590.2 million[31] - The company continues to focus on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs[22] - The company operates as a public benefit corporation, emphasizing its commitment to addressing unmet medical needs[22]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 1000 Spring Street, Silver Spring, MD 20910 (Address of Principal Executive Offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURI ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso® and Orenitram®. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 million, compared to $748.9 million in the third quarter of 2024. "Our commercial an. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Global equity markets experienced broad positive returns in Q3 2025, driven by resilient corporate earnings, enthusiasm for AI, and the U.S. Federal Reserve's first interest rate cut of the year [3][21] - Emerging markets, particularly China, led the gains, supported by a U.S. trade truce and strength in the tech sector [3][4] - The Polaris Global Equity Composite gained 5.04% (net of fees) for the quarter, underperforming the MSCI World Index, which returned 7.36% [5][6] Market Performance - Developed markets saw weaker currencies benefiting export-oriented indices, with Japan's TOPIX Index up 11.0% and the U.K.'s FTSE All-Share Index up 6.9% [4] - The U.S. market, represented by the S&P 500 Index, gained over 8%, primarily due to tech and communication stocks [4] - France and Germany underperformed due to geopolitical and fiscal concerns, with tepid growth projections under new U.S. trade policy [4] Sector Analysis - The healthcare sector was the best performer, with notable gains from pharmaceutical stocks, while financials, consumer discretionary, and IT also contributed positively [5][6] - Health insurers faced challenges, with UnitedHealth Group and CVS Health posting over 10% returns, while Elevance Health's shares dropped sharply due to profit guidance cuts [7] - In IT, Samsung Electronics excelled with strong performance in HBM technology and a significant deal with Tesla for AI chip manufacturing [11] Company Highlights - United Therapeutics Corp. was a top contributor to portfolio performance, driven by positive clinical trial results for its drug Tyvaso, potentially adding $4-5 billion in peak sales [6] - AbbVie, Inc. expects high single-digit revenue growth through 2029, with flagship drugs projected to exceed $31 billion in sales by 2027 [6] - The Carlyle Group Inc. outperformed in the financial sector, up over 20% due to strong fee-based credit and secondaries business [8] Investment Strategy - The current economic environment is characterized by a "two-speed" economy, with a concentrated AI-driven boom amidst subdued growth in other sectors [21][22] - Financials are seen as attractive due to stable net interest margins and loan growth, while defensives like consumer staples and healthcare are expected to perform well [22] - Opportunities in economically-sensitive sectors are being explored, with a focus on industrials benefiting from AI integration and supply chain modernization [22][23]

Core Insights - United Therapeutics (UTHR) is set to expand Tyvaso's label in the respiratory disease sector following positive results from the late-stage TETON-2 study, which demonstrated clinical benefits for idiopathic pulmonary fibrosis (IPF) patients after a year of treatment with nebulized Tyvaso [1][5] Study Results - The TETON-2 study achieved its primary endpoint, showing a 95.6 mL improvement in absolute forced vital capacity (FVC) for Tyvaso-treated patients compared to placebo, indicating enhanced lung function [2] - Treatment benefits were consistent across various patient subgroups, including those with different background therapies, smoking statuses, or oxygen use, and the safety profile was consistent with previous Tyvaso studies [2][6] Regulatory Plans - UTHR intends to meet with the FDA by the end of this year to potentially expedite the regulatory review process once results from the TETON-1 study are available, which is expected in the first half of 2026 [4][11] Market Potential - Approximately 100,000 IPF patients are estimated to be living in the United States, representing a significant untapped market with potential sales from the IPF indication possibly exceeding those from pulmonary arterial hypertension (PAH) [8] Competitive Landscape - The success of Tyvaso in IPF may also benefit smaller biotech companies like Insmed (INSM) and Liquidia Corporation (LQDA), which are developing or marketing treprostinil products [9] - Insmed is working on treprostinil palmitil inhalation powder (TPIP), which offers a once-daily dosing option, potentially positioning it as a competitor in the IPF space [10][12] - Liquidia has recently received FDA approval for Yutrepia, an inhaled treprostinil product, marking it as the first inhaled competitor for PAH and PH-ILD indications, and may also explore its application in IPF [13]

Group 1 - The conference call is focused on the Phase 3 TETON-2 results for United Therapeutics Corporation [1][2] - The call includes forward-looking statements regarding the company's expectations or beliefs about future events, which involve risks and uncertainties [2] - The company emphasizes that remarks made during the call are intended to educate investors and are not for medical decision-making [2] Group 2 - The call is hosted by the Investor Relations Manager, indicating a structured approach to investor communication [1][2] - The presence of Dr. Steve suggests involvement of key personnel in discussing clinical trial progress and results [3]

Core Points - United Therapeutics Corporation held a conference call to discuss the Phase 3 TETON-2 trial results [1][2] - The call included forward-looking statements regarding the company's expectations and beliefs about future events, which are subject to risks and uncertainties [2] Company Developments - The conference call featured remarks on the progress and results of clinical trials related to United Therapeutics' products [2] - The company emphasized that the information shared is intended to educate investors and is not meant for medical decision-making [2]